GlassScriptPhysician profile
Miled A Jabor
NPI 1518908714
$6,880.81
in general payments reported to CMS, 2019-2025
34 companies · $2,070 in 2025
The $2,070 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $235 · 2021: $641 · 2022: $783 · 2023: $1,079 · 2024: $1,709 · 2025: $2,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,835 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,835.43 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,889.69 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $994.33 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $434.07 | 2022-2025 | Tremfya, Stelara, Simponi |
| Aimmune Therapeutics, INC. | $312.22 | 2024-2025 | Zenpep, Vowst |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $259.29 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $244.42 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $217.50 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $196.95 | 2024-2025 | Stelara, Tremfya, Remicade |
| Pfizer INC. | $186.02 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $146.16 | 2024-2025 | Iqirvo, Bylvay |
| Intercept Pharmaceuticals, INC. | $145.24 | 2019-2023 | Ocaliva |
| Daiichi Sankyo INC. | $140.20 | 2020-2024 | Injectafer |
| Qol Medical, LLC | $114.05 | 2022-2024 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $102.27 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $58.62 | 2024 | Omvoh |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $45.18 | 2023-2025 | Dupixent |
| Pentax of America, INC. | $40.15 | 2022 | |
| Ardelyx, INC. | $38.90 | 2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $38.87 | 2024-2025 | Rebyota |
| Allergan, INC. | $36.41 | 2019 | |
| Celgene Corporation | $33.23 | 2021 | |
| Axonics, INC. | $29.93 | 2021 | |
| Amgen INC. | $21.38 | 2025 | Uplizna |
| Mallinckrodt Hospital Products INC. | $21.36 | 2025 | Terlivaz |
| Medtronic, INC. | $19.35 | 2024 | Interstim |
| Ironwood Pharmaceuticals, INC | $18.66 | 2019 | |
| Ucb, INC. | $18.44 | 2019 | |
| Genzyme Corporation | $17.68 | 2025 | |
| Merck Sharp & Dohme LLC | $15.88 | 2022 | |
| Ambu INC. | $13.54 | 2020 | |
| Covidien LP | $11.72 | 2019 | |
| Nestle Healthcare Nutrition INC. | $11.39 | 2021 | |
| Endogastric Solutions, INC | $7.71 | 2024 | Esophyx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$35,647.21 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miled Jabor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.